AstraZeneca PLC
AZN
$187.03
-$2.72-1.43%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.93% | 8.63% | 13.52% | 15.00% | 15.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.93% | 8.63% | 13.52% | 15.00% | 15.48% |
| Cost of Revenue | 15.79% | 11.58% | 1.86% | 16.94% | 15.66% |
| Gross Profit | 8.68% | 7.99% | 16.19% | 14.58% | 15.44% |
| SG&A Expenses | 5.53% | 3.45% | 2.75% | 5.25% | 5.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -25.85% | -16.32% | -40.54% | 7.12% | 76.19% |
| Total Operating Expenses | 9.98% | 8.32% | 6.13% | 11.31% | 12.92% |
| Operating Income | 9.74% | 9.60% | 39.59% | 27.55% | 24.13% |
| Income Before Tax | 38.96% | 42.70% | 44.40% | 29.40% | 24.96% |
| Income Tax Expenses | 66.84% | 31.45% | 43.11% | 32.28% | 37.36% |
| Earnings from Continuing Operations | 33.55% | 45.33% | 44.68% | 28.81% | 22.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 60.00% | -33.33% | 0.00% | -40.00% | -66.67% |
| Net Income | 33.67% | 45.34% | 44.71% | 28.80% | 22.76% |
| EBIT | 9.74% | 9.60% | 39.59% | 27.55% | 24.13% |
| EBITDA | 9.46% | 9.06% | 22.61% | 20.23% | 17.39% |
| EPS Basic | 33.64% | 45.25% | 44.61% | 28.72% | 22.72% |
| Normalized Basic EPS | 9.71% | 10.31% | 43.70% | 31.12% | 27.95% |
| EPS Diluted | 33.57% | 45.29% | 44.97% | 28.81% | 22.35% |
| Normalized Diluted EPS | 9.76% | 10.39% | 43.78% | 31.14% | 27.92% |
| Average Basic Shares Outstanding | 0.03% | 0.06% | 0.06% | 0.06% | 0.03% |
| Average Diluted Shares Outstanding | -0.02% | 0.00% | 0.00% | 0.05% | 0.06% |
| Dividend Per Share | 3.23% | 3.23% | 5.39% | 5.39% | 6.90% |
| Payout Ratio | -0.26% | -0.26% | -0.26% | -0.14% | -0.10% |